Related references
Note: Only part of the references are listed.Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond
Angela Sciacqua et al.
HEART FAILURE REVIEWS (2023)
DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment
Jessica R. Wilson et al.
HYPERTENSION (2022)
Saxagliptin Cardiotoxicity in Chronic Heart Failure: The Role of DPP4 in the Regulation of Neuropeptide Tone
Imre Voros et al.
BIOMEDICINES (2022)
Heart failure: now centre-stage in diabetes
John J. McMurray et al.
LANCET DIABETES & ENDOCRINOLOGY (2022)
GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes
Nikolaus Marx et al.
CIRCULATION (2022)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Naveed Sattar et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Diabetes Management in Patients with Heart Failure
Jia Shen et al.
DIABETES & METABOLISM JOURNAL (2021)
Systematic Review of Glucagon-Like Peptide One Receptor Agonist Liraglutide of Subjects with Heart Failure with Reduced Left Ventricular Ejection Fraction
Farah Hamad et al.
CURRENT DIABETES REVIEWS (2021)
European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure
Petar M. Seferovic et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
Darren K. McGuire et al.
CIRCULATION (2019)
Cardiovascular Effects of New Oral Glucose-Lowering Agents DPP-4 and SGLT-2 Inhibitors
Andre J. Scheen
CIRCULATION RESEARCH (2018)
Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure
John J. V. McMurray et al.
JACC-HEART FAILURE (2018)
Analysis of the Correlation between the Myocardial Expression of DPP-4 and the Clinical Parameters of Patients with Heart Failure
Yuka Kobara et al.
INTERNATIONAL HEART JOURNAL (2018)
Dipeptidyl peptidase-IV in chronic heart failure with reduced ejection fraction
Patricia Lourenco et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome and Cardiac Function in Patients With Diabetes and Heart Failure - Insights From the Ibaraki Cardiac Assessment Study-Heart Failure (ICAS-HF) Registry -
Masayoshi Yamamoto et al.
CIRCULATION JOURNAL (2017)
Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus Secondary Analysis of a Randomized Clinical Trial
Darren K. McGuire et al.
JAMA CARDIOLOGY (2016)
Associations of dipeptidyl peptidase-4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus
Akihiko Sato et al.
ESC HEART FAILURE (2016)
Impact of Either GLP-1 Agonists or DPP-4 Inhibitors on Pathophysiology of Heart Failure
Ayako Takahashi et al.
International Heart Journal (2015)
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
Faiez Zannad et al.
LANCET (2015)
Insulin resistance is associated with impaired cardiac sympathetic innervation in patients with heart failure
S. Paolillo et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING (2015)
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
Benjamin M. Scirica et al.
CIRCULATION (2014)
Sitagliptin Use in Patients With Diabetes and Heart Failure A Population-Based Retrospective Cohort Study
Daniala L. Weir et al.
JACC-HEART FAILURE (2014)
Circulating Dipeptidyl Peptidase IV Activity Correlates With Cardiac Dysfunction in Human and Experimental Heart Failure
Leonardo dos Santos et al.
CIRCULATION-HEART FAILURE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cardiovascular Biology of the Incretin System
John R. Ussher et al.
ENDOCRINE REVIEWS (2012)
Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure
Nelson Gomez et al.
EUROPEAN JOURNAL OF HEART FAILURE (2012)
Clopidogrel 150 vs. 75 mg day-1 in patients undergoing percutaneous coronary intervention: a meta-analysis
P. P. Hao et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure
Que Liu et al.
CARDIOVASCULAR DIABETOLOGY (2010)
Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis
Simon McRae et al.
LANCET (2006)
Insulin signalling and resistance in patients with chronic heart failure
J Kemppainen et al.
JOURNAL OF PHYSIOLOGY-LONDON (2003)